/ Not yet recruitingPhase 3 Non-inferiority, Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic BAC-free Formulation of Latanoprost/Timolol 0.05 mg/mL + 5 mg/mL eye drops, solution in single-dose container vs Xalacom® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension - Non-inferiority study between two Latanoprost/Timolol formulations eye drops solution
/ Not yet recruitingPhase 3 Non-inferiority, Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic BAC-free Formulation of Latanoprost 0.05 mg/mL eye drops, solution in single-dose container vs Xalatan® eye drops in Patients with Open Angle Glaucoma or Ocular Hypertension - Non-inferiority trial between two formulations of Latanoprost 0.05 mg/mL Eye Drops solutions
100 Clinical Results associated with Actrevo GmbH
0 Patents (Medical) associated with Actrevo GmbH
100 Deals associated with Actrevo GmbH
100 Translational Medicine associated with Actrevo GmbH